S-allyl-L-cysteine(S-allyl-L-cysteine)

概要

基本信息

药物类型

小分子化药

别名

+ [2]

靶点-

作用机制-

治疗领域

消化系统疾病其他疾病

在研适应症-

非在研适应症

胃炎消化性溃疡复发性溃疡+ [1]

原研机构

Pharma King Co., Ltd.

在研机构-

非在研机构

Pharma King Co., Ltd.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C6H11NO2S

InChIKeyZFAHNWWNDFHPOH-YFKPBYRVSA-N

CAS号21593-77-1

关联

3

项与 S-allyl-L-cysteine 相关的临床试验

JPRN-UMIN000042281 / CompletedN/A

Concentration of S -Allyl cysteine in blood of intake of food containing aged garlic extract - Concentration of S -Allyl cysteine in blood of intake of food containing aged garlic extract

开始日期2020-11-19

申办/合作机构

Momoya Co. Ltd.

[+1]

NCT02342470 / Completed临床2期

A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled, Dose-finding, Phase IIa Clinical Trial to Efficacy and Safety of PMK-S005 for the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users

The purpose of this study is to evaluate the efficacy and safety by comparing prevention of recurrent peptic ulcer in low-dose aspirin users between PMK-S005 and Placebo.

开始日期2014-11-24

申办/合作机构

Pharma King Co., Ltd.

NCT01762397 / Completed临床1期

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers

The Purpose of a randomized, double-blind, placebo-controlled, single-dose, dose-escalation clinical trial is to explore investigate the safety, tolerability, pharmacokinetics, and food effect of PMK-S005 after oral administration in healthy male volunteers.

开始日期2012-12-01

申办/合作机构

Pharma King Co., Ltd.

100 项与 S-allyl-L-cysteine 相关的临床结果

登录后查看更多信息

100 项与 S-allyl-L-cysteine 相关的转化医学

登录后查看更多信息

100 项与 S-allyl-L-cysteine 相关的专利（医药）

登录后查看更多信息

224

项与 S-allyl-L-cysteine 相关的文献（医药）

2024-12-01·Toxicology Reports

Ameliorating effect of S-Allyl cysteine (Black Garlic) on 6-OHDA mediated neurotoxicity in SH-SY5Y cell line

Article

作者: Yeni, Yesim ; Hacimuftuoglu, Ahmet ; Yildirim, Serkan ; Cicek, Betul ; Bolat, İsmail

Therapeutic approaches based on isolated compounds derived from natural products are more common in preventing diseases involving inflammation and oxidative stress at present. S-allyl cysteine (SAC) is a promising garlic-derived organosulfur compound with many positive effects in cell models and living systems. SAC has biological activity in various fields, enclosing healing in learning and memory disorders, neurotrophic effects, and antioxidant activity. In this study, we purposed to identify the neuroprotective activity of SAC toward 6-OHDA-induced cell demise in the SH-SY5Ycell line. For this purpose, 6-OHDA-induced cytotoxicity, and biochemical, and gene expression changes were evaluated in SH-SY5Y cells. SH-SY5Y cells grown in cell culture were treated with SAC 24 h before and after 6-OHDA application. Then, cell viability, antioxidant parameters, and gene expressions were measured. Finally, immunofluorescence staining analysis was performed. Our results showed that SAC increased cell viability by 144 % at 80 µg/mL with pre-incubation (2 h). It was observed that antioxidant levels were significantly increased and oxidative stress marker levels were decreased in cells exposed to 6-OHDA after pre-treatment with SAC (p<0.05). SAC supplementation also suppressed the increase in pro-inflammation levels (TNF-α/IL1/IL8) caused by 6-OHDA (p < 0.05). While 8-OHdG and Nop10 expressions were observed at a mild level in SAC pretreatment depending on the dose, 8-OHdG, and Nop10 expressions were observed at a moderate level in SAC treatment after 6-OHDA application (p<0.05). Our findings demonstrate the positive effect of pretreatment with SAC on SH-SY5Y cells injured by 6-OHDA, suggesting that SAC may be beneficial for neuroprotection in regulating oxidative stress and neuronal survival in an in vitro model of Parkinson's disease.

2024-11-16·Natural Product Research

Naturally occurring organosulfur compounds effectively inhibits PCSK-9 activity and restrict PCSK-9-LDL-receptor interaction via in-silico and in-vitro approach

Article

作者: Khan, Mohd Shahnawaz ; Waiz, Mohd ; Alvi, Sahir S. ; Ahmad, Saheem ; Khan, M. Salman ; Ahmad, Parvej

The present study intended to divulge the potential role of garlic-derived organosulfur compounds (OSCs) in targeting PCSK-9 and averting its interaction with the EGF-A portion of LDL-R via in-vitro and in-silico analysis. Our in-silico screening data showed that 3-(Propylsulfinyl)-L-alanine (PSA), S-Ethyl-L-cysteine (SEC), alliin, and S-Allyl-L-cysteine (SAC) exhibited higher binding energy (-7.05, -7.00, -6.65, and -6.31 Kcal/mol, respectively) against PCSK-9, among other selected OSCs. Further, the protein-protein interaction study of PCSK-9-OSCs-complex with EGF-A demonstrated a similar binding pattern with E-total values ranging from -430.01 to -405.6 Kcal/mol. These results were further validated via in-vitro analysis which showed that SEC, SAC, and diallyl trisulphide (DAT) exhibited the lowest IC₅₀ values of 4.70, 5.26, and 5.29 µg/mL, respectively. In conclusion, the presented data illustrated that SEC, SAC, and DAT were the best inhibitors of PCSK-9 activity and may have the potential to improve the LDL-R function and lower the circulatory LDL-C level.

2024-10-01·Pharmacological Reports

Therapeutic effects of S-allyl-L-cysteine in a mouse endometriosis model and its immunomodulatory effects via regulation of T cell subsets and cytokine expression

Article

作者: Lim, Whasun ; Song, Gwonhwa ; Park, Wonhyoung ; Park, Sunwoo

BACKGROUNDEndometriosis is a female hormone-dependent gynecological disorder characterized by chronic inflammation. Therefore, the development of novel treatment strategies that can diminish the side effects of the long-term use of hormone-based drugs has been emphasized. S-Allyl-L-cysteine (SAC) is the major constituent of aged garlic extracts. Although the therapeutic effects resulting from the antioxidant properties of SAC have been extensively studied in inflammatory diseases, the therapeutic efficacy of SAC in endometriosis has not been described. In this study, we investigated the therapeutic potential of SAC for endometriosis using a mouse model.METHODSAn endometriosis mouse model was surgically induced, and oral treatment with 30 mg/kg SAC was administered daily for 28 days. The development of endometriotic lesions was assessed by histological analysis, and the expression profiles of adhesion-, apoptosis-, and inflammation-related genes were evaluated by PCR. Flow cytometric analysis of mouse spleen was conducted to assess changes in lymphocyte subpopulations.RESULTSSAC treatment significantly inhibited endometriotic lesion growth. Transcriptional expression analysis revealed the antiadhesion and apoptosis-promoting effects of SAC. In particular, SAC showed an effective immune modulatory response by altering splenic CD4⁺ and CD8⁺ T cell subsets and inflammatory cytokine production in the spleen and endometriotic lesions.CONCLUSIONThis study newly elucidates the inhibitory effects of SAC on the growth of endometriosis in a mouse model and describes its immunomodulatory effects.

100 项与 S-allyl-L-cysteine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
消化性溃疡	临床2期	韩国	Pharma King Co., Ltd.	2014-11-24
复发性溃疡	临床2期	韩国	Pharma King Co., Ltd.	2014-11-24
胃炎	临床2期	韩国	Pharma King Co., Ltd.	2012-12-01
胃溃疡	临床2期	韩国	Pharma King Co., Ltd.	2012-12-01